Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

NCT02812056 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Malignant Neoplasms of Digestive Organs
Malignant Neoplasms of Female Genital Organs
Malignant Neoplasms of Lip Oral Cavity and Pharynx
Malignant Neoplasms of Male Genital Organs

Interventions

DRUG: Alisertib
DRUG: TAK-228

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]